After closing at $1.94 in the most recent trading day, OPKO Health Inc. (NASDAQ: OPK) closed at 1.90, down -2.06%. In other words, the price has decreased by $-0.0400 from its previous closing price. On the day, 2126885 shares were traded. OPK reached its highest trading level at $2.0100 during the session, while it also had its lowest trading level at $1.8900.
Our goal is to gain a better understanding of OPK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 2.30. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
On June 21, 2021, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $7.
On November 25, 2019, Piper Jaffray started tracking the stock assigning a Overweight rating and target price of $2.50.Piper Jaffray initiated its Overweight rating on November 25, 2019, with a $2.50 target price.
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 20 when FROST PHILLIP MD ET AL bought 50,000 shares for $1.94 per share. The transaction valued at 96,888 led to the insider holds 197,556,694 shares of the business.
FROST PHILLIP MD ET AL bought 50,000 shares of OPK for $98,554 on Sep 19. The CEO & Chairman now owns 197,506,694 shares after completing the transaction at $1.97 per share. On Sep 15, another insider, FROST PHILLIP MD ET AL, who serves as the CEO & Chairman of the company, bought 200,000 shares for $2.06 each. As a result, the insider paid 412,900 and bolstered with 197,456,694 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.03 while its Price-to-Book (P/B) ratio in mrq is 0.79.
Stock Price History:
Over the past 52 weeks, OPK has reached a high of $5.25, while it has fallen to a 52-week low of $1.91. The 50-Day Moving Average of the stock is 2.3980, while the 200-Day Moving Average is calculated to be 3.1120.
The stock has traded on average 3.07M shares per day over the past 3-months and 2.62M shares per day over the last 10 days, according to various share statistics. A total of 712.55M shares are outstanding, with a floating share count of 417.29M. Insiders hold about 0.50% of the company’s shares, while institutions hold 25.40% stake in the company. Shares short for OPK as of Jul 14, 2022 were 48.68M with a Short Ratio of 12.73, compared to 54.23M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 7.14% and a Short% of Float of 14.74%.
Its stock is currently analyzed by 5 different market analysts. On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.07 and a low estimate of $-0.06, while EPS last year was $-0.03. The consensus estimate for the next quarter is $-0.08, with high estimates of $-0.04 and low estimates of $-0.14.
Analysts are recommending an EPS of between $-0.09 and $-0.34 for the fiscal current year, implying an average EPS of $-0.24. EPS for the following year is $-0.1, with 5 analysts recommending between $0.08 and $-0.25.
5 analysts predict $326.87M in revenue for the current quarter. It ranges from a high estimate of $354.67M to a low estimate of $302.5M. As of the current estimate, OPKO Health Inc.’s year-ago sales were $442.41M, an estimated decrease of -26.10% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $232.38M, a decrease of -39.80% less than the figure of $-26.10% in the same quarter last year. There is a high estimate of $264.48M for the next quarter, whereas the lowest estimate is $221M.
A total of 4 analysts have provided revenue estimates for OPK’s current fiscal year. The highest revenue estimate was $1.22B, while the lowest revenue estimate was $1.09B, resulting in an average revenue estimate of $1.13B. In the same quarter a year ago, actual revenue was $1.77B, down -36.20% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $1.11B in the next fiscal year. The high estimate is $1.2B and the low estimate is $945.1M. The average revenue growth estimate for next year is down -2.20% from the average revenue estimate for this year.